GLP-1 Drugs Are Finding a New Audience on College Campuses
GLP-1 drugs have become one of the biggest stories in U.S. health care as prescriptions for medicines like Ozempic and Wegovy have surged nationwide. Now that demand is showing up on college campuses, where students are asking about the drugs for weight loss, according to campus clinicians and health officials. The shift is drawing attention because the drugs were first known mostly for diabetes treatment and later for obesity care in adults.
Campus demand is becoming more visible
At colleges across the U.S., student health providers said more young adults are asking about GLP-1 medications, including semaglutide brands Ozempic and Wegovy. The drugs are prescribed for specific medical uses, but campus officials said interest now extends to appearance-driven weight loss as well. That change has become more noticeable as the medicines gained national attention during 2023 and 2024.
University clinicians have also said demand is not always translating into campus prescriptions. Many student health centers do not manage long-term obesity treatment, and some refer students to outside specialists for ongoing care. Officials have not released a nationwide count of campuses seeing increased GLP-1 requests.
What is confirmed is that the audience is getting younger. College-age adults, typically between 18 and 22, are now part of the broader GLP-1 conversation that had centered on older patients. Campus providers said that has raised new questions about screening, follow-up, and whether students understand side effects before starting treatment.
Cost, access, and oversight vary by school
The local impact depends heavily on each campus and health system. Some universities offer student clinic visits and referrals, while others provide only basic counseling and send students off campus for prescriptions. Schools have not released a comprehensive list showing where GLP-1 prescribing is available directly through student health centers.
Cost is another major issue for students. Brand-name GLP-1 drugs can cost hundreds of dollars a month without insurance coverage, and coverage rules vary by plan. Campus officials said that leaves some students seeking discounts, compounded versions, or telehealth options instead of traditional in-person care.
What remains unclear is how widespread regular student use has become on any one campus. Many schools do not publicly break out prescription data for GLP-1 medications among students. Health providers have confirmed growing interest, but a verified national count of student users has not been published.
Social media and broader health trends are driving interest
The broader context is the rapid rise of GLP-1 drugs in the U.S. health market. As these medications became better known through celebrity discussion, social media posts, and direct consumer marketing, younger adults also became more aware of them. Campus health workers said those factors are influencing student questions and expectations.
Doctors have also said the drugs require medical supervision because they can cause side effects and are not appropriate for every patient. That matters on campuses, where students may move between home doctors, telehealth platforms, and student clinics during the academic year. Consistent follow-up can be difficult when care is spread across multiple providers.
For students and families, the practical takeaway is that access will likely depend on insurance, campus health center policy, and whether a student meets prescribing guidelines. Universities have not announced any broad national policy change tied to GLP-1 demand. For now, campus interest appears to reflect a wider U.S. shift in who is seeking these medications and where those conversations are happening.
